Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Emedastine is a novel, potent, high affinity, selective, second generation H1-receptor antagonist with pre-clinically well-documented anti-allergic effects. Emedastine's affinity for H1-receptors is 1.3 ±0.1 nM, while its affinity for H2- and H3-receptors is significantly lower, with K1 values of 49,067 ± 11,113 nM and 12,430 ± 1,282 nM, respectively. Since emedastine exhibits pharmacodynamic qualities similar to those of cetirizine, it is a suitable substitute drug with H1-receptor antagonist qualities that is also safe. To support the possible advantages of cetirizine over emedastine following a single dose, more extensive research may be required.
Targets |
H1 Receptor ( Ki = 1.3 nM ); H2 Receptor ( Ki = 49067 nM ); H3 Receptor ( Ki = 12430 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
Emedastine was significantly weaker at H2- (K1 = 49,067 +/- 11,113 nM) and H3- (Ki = 12,430 +/- 1,282 nM) receptors, but showed the highest affinity for H1-receptors (dissociation constant, Ki = 1.3 +/- 0.1 nM). The results showed that emedastine is a highly selective H1-receptor antagonist, with ratios of 37744, 9562, and 4 for H2:H1, H3:H1, and H2:H3 receptor affinities, respectively. Emedastine's H1-selectivity was significantly higher than pyrilamine's (H2:H1, H3:H1, and H2:H3 ratios of 11887, 12709, and 1, respectively). The antihistamines ketotifen (858, 1752, 0.5), levocabastine (420, 82, 5), pheniramine (430, 312, 1), chlorpheniramine (5700, 2216, 3), and antazoline (1163, 1110, 1) also demonstrated a notable lack of H1 selectivity in comparison to emedastine. Mededastine's ability to counteract histamine-induced phosphoinositide turnover in human trabecular meshwork cells was found to be potent (IC50 = 1.44 +/- 0.3 nM), which was in good agreement with its affinity for binding the H1 receptor site. These findings show that the most selective histamine antagonist for the H1-histamine receptor is emedastine, a histamine antagonist with high affinity and potency.
|
|
Animal Protocol |
Male ICR mice 5-6 weeks of age
0.03, 0.1, 0.3 mg/kg Orally; 30 min before pruritogen injection |
|
References |
|
Molecular Formula |
C17H26N4O
|
|
---|---|---|
Molecular Weight |
302.41
|
|
Exact Mass |
302.21
|
|
CAS # |
87233-61-2
|
|
Related CAS # |
Emedastine-13C,d3 fumarate; Emedastine difumarate; 87233-62-3
|
|
Appearance |
Oil
|
|
SMILES |
CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
|
|
InChi Key |
KBUZBQVCBVDWKX-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
|
|
Chemical Name |
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3068 mL | 16.5338 mL | 33.0677 mL | |
5 mM | 0.6614 mL | 3.3068 mL | 6.6135 mL | |
10 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05318157 | Recruiting | Drug: AIT drops Drug: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops |
Allergic Rhinitis | Beijing Tongren Hospital | March 31, 2022 | Phase 4 |
NCT00133627 | Completed | Drug: Ketotifen | Seasonal Allergic Conjunctivitis | Novartis | April 2005 | Phase 4 |